Expansion into new geographies and enhanced approval for STIMULAN to treat bacterial infection Keele, UK, 15 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to provide the following business update. Read more…
Egetis concludes, based on recent regulatory interactions, that available Triac Trial I data together with recently published long-term data are sufficient for a Marketing Authorisation Application in Europe Having all clinical data required for regulatory submission already at hand significantly reduces the remaining risk for Emcitate Revised submission timelines will be communicated as soon as […]
OSLO/LONDON: 13 DECEMBER, 2021: EXACT Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that its Interim Chief Executive Officer and Chief Financial Officer, Dominic Moreland and Chief Medical Officer, Dr Hilary McElwaine-Johnn will present a corporate overview via […]
New Nordic fund focused on high-impact medical innovation Nine investments made over the first 16 months in early and late-stage healthcare companies. Two portfolio companies IPO’ed on NASDAQ New York December 9, 2021, Stockholm & Copenhagen: Eir Ventures Partners AB (“Eir Ventures” or “the Fund”), a Nordic Life Science Venture Capital manager, today announced the […]
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences from December 2021 to March 2022: BioFIT Digital 7-9 December 2021 Tim Van Assche, VP of Business Development and Alliance will be in attendance. ESMO Immuno-Oncology Online Congress 8-11 […]
